Engineered immune cells take on stomach cancer in new trial
NCT ID NCT07179484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1b trial is testing a personalized cell therapy called CT041 CAR-T for people with advanced stomach or gastroesophageal junction cancer. After completing standard first-line treatment, 20 participants will receive up to three infusions of their own engineered immune cells. The goal is to see if this approach can delay cancer progression and improve survival, while monitoring safety and how the cells behave in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT041 autologous CAR-T cell injection
What this could lead to
If successful, this could offer a new treatment option to control advanced gastric cancer after initial therapy, potentially extending time without disease progression.
What could go wrong
This is a small, early-phase trial (20 participants) focused on safety and dosing, so results may not confirm effectiveness. CAR-T therapy carries risks like cytokine release syndrome and neurological side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BeijingGoBroadH
RECRUITINGBeijing, 100142, China
Contact